论文部分内容阅读
目的观察新型抗血小板聚集药物吲哚布芬与华法林在心源性脑栓塞二级预防中的作用。方法脑栓塞患者二级预防治疗组采用吲哚布芬,对照组采用华法林治疗。结果对照组和治疗组的脑栓塞复发率分别为15%和10%,P>0.05,两组之间差异无统计学意义。对照组和治疗组的血小板聚集功能标准差分别为45.3和50.6,对照组和治疗组的INR标准差分别为0.5和0.03,对照组和治疗组的出血率分别为25%和10%,差异均有统计学意义。结论吲哚布芬在心源性脑栓塞二级预防中的作用与华法差异林无统计学意义,对凝血功能和INR无明显影响,不需要频繁监测凝血功能和INR,皮肤、内脏和脑出血的发生率明显低于华法林组。从而在治疗的安全性、依从性方面优于华法林。
Objective To observe the role of indobufen, a new anti-platelet aggregation drug, and warfarin in secondary prevention of cardioembolic embolism. Methods Indobufen was used in the secondary prevention group and the control group was treated with warfarin. Results The recurrence rates of cerebral embolism in the control group and the treatment group were 15% and 10%, respectively, P> 0.05. There was no significant difference between the two groups. The standard deviation of platelet aggregation in the control group and the treatment group were 45.3 and 50.6, respectively. The standard deviation of INR was 0.5 and 0.03 in the control group and the treatment group, while the bleeding rates in the control group and the treatment group were 25% and 10%, respectively There is statistical significance. Conclusion Indobufen has no significant difference in the secondary prevention of cardiogenic cerebral embolism compared with that of the warfarin group, and has no significant effect on the coagulation function and INR, and does not require frequent monitoring of coagulation function and INR, skin, internal organs and intracerebral hemorrhage The incidence was significantly lower than the warfarin group. Thus in the treatment of safety, compliance is better than warfarin.